Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.

被引：0
|
作者：
Ran, Tao
Medhekar, Rohan
Fu, Alex Z.
Patel, Sharmila
Kaila, Shuchita
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] Georgetown Univ, Med Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    BMC CANCER, 2024, 24 (01)
  • [2] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (05) : 679 - 686
  • [3] Comparison of lenalidomide, bortezomib, dexamethasone vs bortezomib, cyclophosphamide, dexamethasone as an induction regimen in newly diagnosed myeloma patients eligible for intensive chemotherapy
    Van de Wyngaert, Zoe
    Malard, Florent
    Marjanovitch, Zora
    Alsuliman, Tamim
    Ikhlef, Souhila
    Mohty, Mohamad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S137 - S137
  • [4] A 28 Day Schedule for Lenalidomide Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Chari, Ajai
    Roper, Nitin
    Jagannath, Sundar
    BLOOD, 2011, 118 (21) : 1272 - 1273
  • [5] Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.
    Knop, Stefan
    Langer, Christian
    Engelhardt, Monika Martha
    Wangemann, Johanne
    Muegge, Lars Olof
    Bassermann, Florian
    Schaefer-Eckart, Kerstin
    Blau, Igor W.
    Wolleschak, Denise
    Reichle, Albrecht
    von Metzler, Ivana
    Metzner, Bernd
    Rollig, Christoph
    Hertenstein, Bernd
    Pfreundschuh, Michael
    Brummendorf, Tim H.
    Gramatzki, Martin
    Ritgen, Mattias
    Held, Swantje
    Einsele, Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [7] Thalidomide and dexamethasone in newly diagnosed multiple myeloma.
    McHugh, Johnny
    O'Ceallaigh, Cathal
    Keane, Colm
    Otridge, Brian W.
    O'Gorman, Peter
    BLOOD, 2006, 108 (11) : 370B - 370B
  • [8] Thalidomide and dexamethasone in newly diagnosed multiple myeloma.
    McHugh, J
    Keane, C
    Otridge, BW
    Thornton, P
    O'Gorman, P
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [9] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    BLOOD, 2017, 130
  • [10] Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
    Knop, Stefan
    Langer, Christian
    Engelhardt, Monika Martha
    Bassermann, Florian
    Schreder, Martin
    Muegge, Lars-Olof
    Schaefer-Eckart, Kerstin
    Blau, Igor W.
    Wolleschak, Denise
    Reusch, Julia
    von Metzler, Ivana
    Metzner, Bernd
    Dechow, Tobias
    Hertenstein, Bernd
    Duerk, Heinz
    Theurich, Sebastian
    Stuebig, Thomas
    Kroenke, Jan
    Held, Swantje
    Einsele, Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345